BioSpace News Archive

Fortress Biotech, Inc. today announced financial results and recent corporate highlights for the full-year ended December 31, 2021.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company’s President & Chief Executive Officer will give an oral presentation in the Next Generation Kinase Inhibitors Summit.

We have had an incredibly productive year, where we observed a 100% complete response rate in our multi-center U.S. pilot trial of skin cancers led by Memorial Sloan Kettering, we received two Food and Drug Administration breakthrough device designations, one in recurrent glioblastoma and one in certain skin cancers, and we completed our acquisition of Healthcare Capital Corp and became a Nasdaq listed company.

Boehringer Ingelheim announced today new data from the pivotal Phase II Effisayil™ 1 trial, presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it will appoint Flavia H. Pease as its next Chief Financial Officer, succeeding David R. Smith, who previously announced on January 11th that he intends to retire.

Pipeline Therapeutics today announced that the U.S. Food and Drug Administration (FDA) cleared the company to initiate its Phase 1b/2a clinical trial of PIPE-307 in patients with relapsing-remitting multiple sclerosis (RRMS).

Immunome, Inc. today reported financial results for the fourth quarter ended December 31, 2021 and provided a corporate update.

Alzamend Neuro, Inc. today announced that it has received the full data set from its Phase 1 clinical trial for AL001.

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”) is pleased to announce that, further to the Company’s news release dated February 23, 2022, it has entered into a definitive agreement (the “ Agreement ”) dated March 24, 2022 with Praesidio Health Inc. (“ Praesidio ”). Pursuant to the Agreement, the Company will acquire all of the issued and outstanding shares in the capital of Praesidio.

Diadem SpA, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced the closing of the first tranche of a €10 million equity financing.